New Delhi, March 14 Zydus Lifesciences announced on Saturday that its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its Desidustat tablets, used to treat renal anemia.
The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd.
CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, obtained an exclusive license for the drug from Zydus in 2020.
Desidustat tablets are administered orally to treat anemia in patients with Chronic Kidney Disease (CKD). CKD involves the gradual loss of kidney function and eventually leads to kidney failure.
"We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilling lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement.
The company is happy to partner with CMS and is confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China, he added.
Desidustat is discovered, developed, and marketed by Zydus in India under the brand name Oxemia. More than 1 lakh CKD patients in India have been successfully treated with Oxemia since its launch in 2022, the drug firm stated.
There is still a large unmet need in the treatment of anemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China.